Breaking News

Cobra Biologics Gains Approval for R&D Tax Credit

April 1, 2014

Offers R&D incentive for French companies

Cobra Biologics has been recognized by the French Ministry of Higher Education and Research (MESR) as an approved service provider for its antibody and recombinant protein services for the period 2013 to 2015. The approval allows French companies that outsource their R&D programs to Cobra’s centre of excellence, to receive a research tax credit.
 
The tax credit, which covers 30% of all R&D expenses up to €100 million, and 5% above this threshold, aims to encourage R&D efforts and enhance investments in France. 

Peter Coleman, chief executive officer of Cobra Biologics, said, “CIR is a real benefit to our French customers as it encourages them to invest in innovative drugs that are ultimately the driving force for the medicines of tomorrow.”

Related Contract Manufacturing:

  • When Quality Meets Confidence

    When Quality Meets Confidence

    Dr. Fadia AlKhalil, Vice President of Global Business Development for Laboratory Services, SGS ||November 9, 2016
    A look at global account management for R&D outsourcing

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus